BEGIN:VCALENDAR VERSION:2.0 PRODID:-//BioNJ - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://bionj.org X-WR-CALDESC:Events for BioNJ REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/New_York BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20230312T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20231105T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20240310T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20241103T060000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0500 TZOFFSETTO:-0400 TZNAME:EDT DTSTART:20250309T070000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST DTSTART:20251102T060000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/New_York:20241010T073000 DTEND;TZID=America/New_York:20241010T163000 DTSTAMP:20260503T045723 CREATED:20240318T181526Z LAST-MODIFIED:20241002T120610Z UID:11216-1728545400-1728577800@bionj.org SUMMARY:2024 BioNJ C-Suite Summit DESCRIPTION:THIS EVENT IS CLOSED TO THE MEDIA \n\n\n\nAn Inflection Point for Innovation in Life Sciences\n\n\n\nThursday\, October 10\, 2024 | 7:30 a.m.-4:30 p.m. Bridgewater Marriott\, 700 Commons Way\, Bridgewater\, NJ \n\n\n\n\nRegister Today\n\n\n\nBecome a Sponsor\n\n\n\n\nAgainst a backdrop of change\, the biopharmaceutical industry – and the next wave of innovation – are at an inflection point. Join us to reflect on the state of innovation in life sciences and how companies can best navigate through this period of continued change. \n\n\n\n \n \n \n \n \n \n\n TimeAGENDA\n\n\n\n \n 7:30 a.m. – 8:15 a.m.Registration & Networking Breakfast \n \n \n8:15 a.m. – 8:20 a.m.\n\n Welcome & Opening Remarks \n\nDebbie Hart\, President & CEO\, BioNJ\nEmer Leahy\, MBA\, Ph.D.\, President & CEO\, PsychoGenics & Chair\, BioNJ\n\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeINNOVATION\n\n\n\n \n \n8:20 a.m. – 8:50 a.m.\n\nKeynote: The Next Wave of Innovation in Life Sciences \nLife sciences leaders are navigating a period of exciting innovation. Novel modalities and mechanisms of action have helped the industry address previously stubborn unmet needs. Over the past 10 years\, R&D spend has increased\, the pipeline has become more diverse and new asset approvals have accelerated. Looking ahead\, policy reforms (e.g.\, IRA)\, a rapid proliferation in technological resources (e.g.\, AI\, mRNA platforms) and a rise in cross-company collaborations suggest further change and opportunity. Join us in reflecting on what the future of life sciences innovation holds\, and implications for large cap pharma companies\, biotechs and life sciences investors.  \n\nBrandon Parry\, MBA\, Sr. Partner\, McKinsey & Company\n\n \n \n \n8:50 a.m. – 9:45 a.m.\n\nPanel: Harnessing Change to Deliver Impactful Innovation \nIndustry leaders will reflect on the state of innovation\, expected industry shifts\, latest thinking on development paradigms\, portfolio shifts\, the lasting implications of policy reforms\, the impact of technological evolutions\, talent priorities and more. \n\nGarrett Ingram\, President & CEO\, Cipla Therapeutics\nWill Lewis\, MBA\, J.D.\, Chair & CEO\, Insmed\nClive Meanwell\, M.D.\, Chair & Partner\, Population Health Partners\nTarek Rabah\, MBA\, President & CEO\, Otsuka Pharmaceuticals\nScott White\, MBA\, Chief Operations Officer\, NA Innovative Medicine\, Johnson & Johnson\nConversation Leader: Harriet Keane\, Ph.D.\, Partner\, McKinsey & Company\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimePOLICY\n\n\n\n \n \n9:45 a.m. – 10:15 a.m.\n\nFireside Chat: Policy Uncertainties in an Election Year \nThe past 18 months have borne witness to a rapidly evolving policy landscape (including but not limited to the IRA\, IP\, BIOSECURE) – with expected evolutions on the horizon compounded by a tumultuous election season. With the presidential election just a few weeks away\, this session will explore potential health policy changes and implications for industry leaders. \n\nHon. Jim Greenwood\, Former Congressman & Former President & CEO\, BIO \nHeather Meade\, Principal\, EY\nConversation Leader: Lisa LeCointe-Cephas\, J.D.\, Partner\, Compliance & Investigations & Global Chair\, Life Sciences Sector\, DLA Piper\n\n \n \n 10:15 a.m. – 10:30 a.m.\nNetworking Break \n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeMARKET ACCESS\n\n\n\n \n 10:30 a.m. – 11:15 a.m.\nPanel: Market Access & ReimbursementThe market access landscape is intricate and constantly evolving\, with payers persistently refining their business models and strategies. This panel will explore the essential groundwork for securing optimal reimbursement and payer coverage\, which are crucial for ensuring Patient access to treatments and\, ultimately\, improving Patient care. The panel will also address key issues manufacturers face including changing legislation\, consolidation\, M&A\, gross to net and commercial launch planning. \n\nPaul Hunter\, Vice President\, Market Access and Commercial Operations\, Halozyme\nChristopher Jackson\, J.D.\, Managing Member\, The Law Office of Christopher S. Jackson\nJake McDowell\, Vice President\, Head\, Market Access\, Pricing and Value\, Partner Therapeutics\nConversation Leader: Tom Evegan\, Principal\, Strategy & Management Consulting; National Consulting Leader Life Sciences\, RSM\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeTALENT\n\n\n\n \n 11:15 a.m. – 12:00 p.m.\nPanel: Topics in Talent: Attraction\, Retention & DiversityIn the life sciences sector\, talent development is crucial for fostering innovation and addressing complex challenges. Companies are focused on developing the next generation of talent by providing opportunities for education\, training and mentorship. Additionally\, there is a growing emphasis on upskilling and reskilling talent to leverage AI and other advanced technologies for greater efficiency and effectiveness. This discussion will explore key learnings from workplace evolutions and strategies companies can and must adopt such as equity. \n\nBritt Byers\, Executive Vice President\, Human Resources NA\, Kyowa Kirin\nVikki Conway\, Sr. Vice President & Head\, Human Resources\, U.S.\, Teva Pharmaceuticals\nKiran Dattani\, MPH\, MBA\, Customer Success\, Transformation\, Strategy & Architecture\, Google Cloud Healthcare & Life Sciences\, Google\nConversation Leader: Jan Campbell\, Managing Partner Pharmaceuticals & Biotechnology\, Korn Ferry\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeRESEARCH & DEVELOPMENT\n\n\n\n \n 12:00 p.m. – 12:30 p.m.\nFireside Chat: Research & Development in Mental HealthWith Global Mental Health Day as the backdrop\, this discussion features two pioneers in mental health research and development and will explore the challenges in developing therapeutics in the mental health space and how they can provide learnings in other areas. \n\nHusseini Manji\, M.D.\, F.R.C.P.C.\, Professor\, Oxford University; Co-Chair\, UK Govt MH Mission; Former Global Head\, Neuroscience\, Janssen/Johnson & Johnson\nConversation Leader: Emer Leahy\, MBA\, Ph.D.\, President & CEO\, PsychoGenics & Chair\, BioNJ\n\n \n \n 12:30 p.m. – 1:30 p.m.\nNetworking Lunch \n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeCOMMERCIALIZATION & PATIENT SERVICES\n\n\n\n \n 1:30 p.m. – 2:15 p.m.\nPanel: Continued Evolutions in Go-to-Market Models Including Patient ServicesThe continued evolution of the go-to-market (GTM) commercial model in life sciences has been characterized by a shift from push to pull strategies\, the development of novel roles that rethink traditional functional boundaries in a compliant manner\, and a simplification of the customer interface. This talk will explore how these approaches can enhance and improve Patient access to treatments given the complex journey that is the Patient experience. Getting it right can have a major impact on Patient outcomes\, as Patient experience in healthcare continues to lag. personalized journeys. \n\nJohn Harlow\, Chief Commercial Officer\, Melinta Therapeutics\nRohan Jain\, General Manager\, Commercial\, Nusano\nGina Murdoch\, MBA\, President & CEO\, Multiple Sclerosis Association of America\nConversation Leader: Haripriya Jain\, MS\, MBA\, Executive Director\, Global Value & Access Consulting\,  Evidera\, part of Thermo Fisher Scientific \n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeCAPITAL MARKETS\n\n\n\n \n 2:15 p.m. – 3:00 p.m.\nPanel: Evolving Capital Markets & Implications for InnovationThe life sciences industry market cap has more than tripled in a decade despite more recent challenges. This discussion will explore the latest funding environment (e.g.\, IPOs) and implications for industry. \n\nAamir Mecklai\, Managing Director\, Healthcare Investment Banking\, Bank of America\nChristopher Mortko\,MBA\, Ph.D.\, Vice President\, Business Development & Licensing\, Merck & Co.\nMonika Vnuk\, M.D.\, Sr. Vice President\, Global Partnering & Business Development\, Sanofi\nConversation Leader: Arda Ural\, MBA\, Ph.D.\, Americas Life Sciences Sector Leader\, EY\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n\n TimeAI & TECHNOLOGY\n\n\n\n \n 3:00 p.m. – 3:45 p.m.\nPanel: The Digital & AI Era in the Biopharma Industry: How Can Companies Across Functions Transition from Hype Into Reality?In the current environment\, the biopharmaceutical industry is experiencing a transformative shift towards digitalization and AI adoption\, promising improved efficiency\, innovation and Patient outcomes. However\, for companies to transition successfully from the hype surrounding these technologies into tangible benefits\, they must integrate digital and AI solutions across functions\, prioritize data-driven decision-making and foster a culture of innovation and adaptability. \n\nSydney Klein\, Chief Information Security Officer & Head of IT Core Services\, Bristol Myers Squibb\nHisham Hamadeh\, Ph.D.\, Sr. Vice President & Global Head\, Data Science & AI\, Genmab\nKeith Koharski\, MBA\, Executive Director\, Global Development IT\, Regeneron\nDeiva Ramachandran\, Ph.D.\, Partner\, Generative AI-Automation Practice Leader\, Healthcare\, Life Sciences\, State & Local Government\, IBM\nConversation Leader: Donna Conroy\, Founder\, CEO\, SciMar ONE\n\n \n \n \n \n \n \n\n\n\n\n\n \n \n \n \n \n \n \n \n \n\n\n\n\n\nJoin us on October 10 for this important conversation. Registration is $695 for BioNJ Members and $895 for Future Members. (BioNJ is pleased to have maintained our pricing unchanged for the past three years.) Click here to register. \n\n\n\nThank You to Our Sponsors URL:https://bionj.org/event/2024-bionj-c-suite-summit/ LOCATION:New Jersey CATEGORIES:BioNJ Event ATTACH;FMTTYPE=image/png:https://bionj.org/wp-content/uploads/2024/03/CSuite-Summit-2024.png END:VEVENT END:VCALENDAR